Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7747323 | 1.00 | BDKRB2 (1.00) | BDKRB2 | |
| Hydrochloric Acid SCHEMBL7748220 | 0.99 | BDKRB2 (1.00) | BDKRB2 | |
| Hydrochloric Acid SCHEMBL7748223 | 0.99 | BDKRB2 (1.00) | BDKRB2 | |
| SCHEMBL7838923 | 0.95 | BDKRB2 (0.90) | BDKRB2 | |
| SCHEMBL7746470 | 0.95 | BDKRB2 (0.90) | BDKRB2 | |
| SCHEMBL7838925 | 0.95 | BDKRB2 (0.90) | BDKRB2 | |
| SCHEMBL7746468 | 0.95 | BDKRB2 (0.90) | BDKRB2 | |
| SCHEMBL7742720 | 0.94 | BDKRB2 (0.89) | BDKRB2 | |
| SCHEMBL7742715 | 0.94 | BDKRB2 (0.89) | BDKRB2 | |
| Hydrochloric Acid SCHEMBL7748481 | 0.94 | BDKRB2 (0.90) | BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. | 2016-02-04 | — | — | US | disclosed |
| EP-0622361-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6169095-B1 | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES IN THE EYE, SUCH AS ALLERGY, INFLAMMATION AND PAIN OF THE EYE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | BDKRB2, BDKRB1, HRH2 | BDKRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.